Prialt is a drug owned by Tersera Therapeutics Llc. It is protected by 5 US drug patents filed from 2013 to 2017. Out of these, 3 drug patents are active and 2 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 01, 2024. Details of Prialt's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5795864 | Stable omega conopetide formulations |
Jun, 2015
(9 years ago) |
Expired
|
| US5364842 | Method of producing analgesia |
Dec, 2016
(7 years ago) |
Expired
|
| US8765680 | Method for administering omega-conopeptide |
Oct, 2024
(2 months from now) | Active |
| US9707270 | Method for administering ω-conopeptide |
Oct, 2024
(2 months from now) | Active |
| US8653033 | Method for administering omega-conopeptide |
Oct, 2024
(2 months from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Prialt's patents.
Latest Legal Activities on Prialt's Patents
Given below is the list of recent legal activities going on the following patents of Prialt.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 15 Dec, 2021 | US8765680 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 04 Aug, 2021 | US8653033 |
| Email Notification | 26 Apr, 2021 | US8765680 |
| Change in Power of Attorney (May Include Associate POA) | 26 Apr, 2021 | US8653033 |
| Email Notification | 26 Apr, 2021 | US8653033 |
| Change in Power of Attorney (May Include Associate POA) | 26 Apr, 2021 | US8765680 |
| Correspondence Address Change | 23 Apr, 2021 | US8653033 |
| Change in Power of Attorney (May Include Associate POA) | 23 Apr, 2021 | US9707270 |
| Correspondence Address Change | 23 Apr, 2021 | US8765680 |
| Email Notification | 23 Apr, 2021 | US9707270 |
US patents provide insights into the exclusivity only within the United States, but Prialt is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Prialt's family patents as well as insights into ongoing legal events on those patents.
Prialt's family patents
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Generic Launch
Generic Release Date:
Prialt's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 01, 2024 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Prialt Generics:
There are no approved generic versions for Prialt as of now.
About Prialt
Prialt is a drug owned by Tersera Therapeutics Llc. It is used for managing severe chronic pain through intrathecal infusion in patients also receiving morphine. Prialt uses Ziconotide Acetate as an active ingredient. Prialt was launched by Tersera in 2004.
Market Authorisation Date:
Prialt was approved by FDA for market use on 28 December, 2004.
Active Ingredient:
Prialt uses Ziconotide Acetate as the active ingredient. Check out other Drugs and Companies using Ziconotide Acetate ingredient
Treatment:
Prialt is used for managing severe chronic pain through intrathecal infusion in patients also receiving morphine.
Dosage:
Prialt is available in injectable form for intrathecal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 500MCG/5ML (100MCG/ML) | INJECTABLE | Prescription | INTRATHECAL |
| 100MCG/1ML (100MCG/ML) | INJECTABLE | Prescription | INTRATHECAL |
| 200MCG/2ML (100MCG/ML) | INJECTABLE | Discontinued | INTRATHECAL |
| 500MCG/20ML (25MCG/ML) | INJECTABLE | Prescription | INTRATHECAL |